Qiagen N.V.
QGENHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Qiagen N.V. (QGEN) is listed under Diagnostics & Research. Valued at $10.41B, QGEN is a large-cap name in its sector. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Market Cap
$10.41B
Beta
0.61
P/E (TTM)
25.58
P/E (Fwd)
19.28
EPS (TTM)
$1.97
EPS (Fwd)
$2.61
ROE
11.9%
ROA
5.9%
Cash
$793.5M
Total Debt
$1.65B
Free CF
$372.9M
52W Change
4.1%
Annual Financials
Cash vs Debt
Where QGEN stands vs its 150-day and 200-day moving averages
As of the October 8, 2026 close, QGEN finished 12.09% above its 150-day moving average ($39.96) and 6.14% above its 200-day moving average ($42.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QGEN overbought or oversold?
At the October 8, 2026 close, QGEN's RSI(14) was 51.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $793.5M in cash, though total debt stands at $1.65B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $372.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.14B (2022) to $2.09B (2025).
The relatively low beta of 0.61 suggests QGEN is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing QGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.